Meeting
2019 ASCO Annual Meeting
Safety, efficacy, and biomarker analysis of pyrotinib in combination with capecitabine in HER2-positive metastatic breast cancer patients: A phase I clinical trial.
Authors
Fei Ma
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Fei Ma , Qiao Li , Xiuwen Guan , Shanshan Chen , Zongbi Yi , Bo Lan , Puyuan Xing , Ying Fan , Jiayu Wang , Yang Luo , Peng Yuan , Ruigang Cai , Pin Zhang , Qing Li , Binghe Xu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT02361112
Citation
J Clin Oncol 37, 2019 (suppl; abstr 1035)
DOI
10.1200/JCO.2019.37.15_suppl.1035
Abstract #
1035
Poster Bd #
116
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Pyrotinib monotherapy or pyrotinib in combination with capecitabine could significantly prolong progression-free survival and overall survival in patients with HER2-positive metastatic breast cancer.
First Author: Xiuwen Guan
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Development and application of an ultra-sensitive ctDNA mutation profiling assay in monitoring therapy response and drug resistance.
First Author: Tom Zhang
Poster
2023 ASCO Annual Meeting
Distinguishing primary mucinous ovarian tumors from metastases of non-gynecologic mucinous cancers: Can we leverage next-generation sequencing?
First Author: Muhammad Danyal Ahsan
Poster
2021 ASCO Annual Meeting
Pyrotinib plus capecitabine for HER2-positive metastatic breast cancer patients with brain metastases (PERMEATE): A multicenter, single-arm phase II study.
First Author: Min Yan